Idera Announces Appointment of Robert A. Doody Jr. as Vice President of Investor Relations and Corporate Communications

CAMBRIDGE, Mass., Dec. 2, 2014 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. IDRA, a clinical-stage biopharmaceutical company developing nucleic acid therapeutics for cancers and rare diseases, announced that it has appointed Robert A. Doody Jr. as Vice President, Investor Relations and Corporate Communications.

Vincent J. Milano, Chief Executive Officer of Idera Pharmaceuticals, stated, "I am thrilled to have the opportunity to work with Bob again. Bob has tremendous credibility with investors and has earned their confidence as a world-class investor relations professional. In addition, his passion and energy fit well with the people of Idera and our needs."

Mr. Doody, most recently served for the past eight years as Head of Investor Relations of ViroPharma, which was acquired by Shire Pharmaceuticals in January 2014. During his tenure at ViroPharma the company transformed to a leading developer of innovative therapies for rare diseases, highlighted by its lead product, Cinryze, for the treatment of hereditary angioedema in the United States and Europe.

Prior to joining ViroPharma, Mr. Doody spent several years at the healthcare communications firm, Dorland Sweeney Jones in Philadelphia. He received his Bachelor of Arts degree in Communications from Rowan University. Mr. Doody also served honorably in the United States Navy.

About Idera Pharmaceuticals

Idera Pharmaceuticals is a clinical-stage biopharmaceutical company developing a novel therapeutic approach for the treatment of genetically defined forms of B-cell lymphoma and rare diseases. Idera's proprietary technology involves creating novel nucleic acid therapeutics designed to inhibit over-activation of Toll-like receptors (TLRs). In addition to its TLR programs, Idera is developing gene silencing oligonucleotides (GSOs) that it has created using its proprietary technology to inhibit the production of disease-associated proteins by targeting RNA. To learn more about Idera, visit www.iderapharma.com.